Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$148.58 USD

148.58
5,042,315

-0.69 (-0.46%)

Updated May 6, 2024 04:00 PM ET

After-Market: $148.74 +0.16 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 22% (196 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for JNJ

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Johnson & Johnson [JNJ]

Reports for Purchase

Showing records 461 - 480 ( 497 total )

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 461

09/02/2011

Industry Report

Pages: 5

LIFE SCIENCES -The Week Ahead in Life Sciences - Upcoming Events for the Week of September 4

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 462

07/29/2011

Company Report

Pages: 14

Price: 24.95

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 463

07/22/2011

Company Report

Pages: 14

Revitalised Pharma pipeline & aggressive new product launch strategy to drive growth.....

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 50.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 464

07/20/2011

Company Report

Pages: 2

Q2 Results show accelerating growth

Provider: G.RESEARCH, LLC

Analyst: JONAS J

Price: 10.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 465

07/20/2011

Company Report

Pages: 11

Price: 24.95

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 466

07/14/2011

Daily Note

Pages: 2

MODEL STOCK PORTFOLIO -CONSERVATIVE GROWTH

Provider: J.J.B. Hilliard, W.L. Lyons

Price: 10.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 467

06/22/2011

Industry Report

Pages: 28

Pharmaceuticals Food For Thought

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 75.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 468

06/21/2011

Industry Report

Pages: 25

Upgrading Global Pharma sector to ‘Moderate Outperform’

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 75.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 469

06/16/2011

Company Report

Pages: 2

Exits the stent market

Provider: G.RESEARCH, LLC

Analyst: JONAS J

Price: 10.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 470

06/02/2011

Company Report

Pages: 13

Revitalised Pharma pipeline & aggressive new product launch strategy to offset patent expiry related slowdown.

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 50.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 471

06/02/2011

Company Report

Pages: 13

Upgrade To Moderate Outperform : Revitalised Pharma pipeline & aggressive new product launch strategy to offset patent expiry related slowdown...

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 50.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 472

05/25/2011

Company Report

Pages: 15

Price: 24.95

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 473

04/21/2011

Company Report

Pages: 14

Raising our CY11 estimates in view of expected forex benefits

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 50.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 474

04/20/2011

Company Report

Pages: 12

Price: 24.95

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 475

04/19/2011

Company Report

Pages: 9

First Quarter Revenue Surprisingly Strong

Provider: J.J.B. Hilliard, W.L. Lyons

Analyst: O'NEIL S

Price: 25.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 476

02/08/2011

Company Report

Pages: 12

Price: 24.95

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 477

02/01/2011

Company Report

Pages: 15

Delay in resolution of McNeil recall/OTC issues & increased generic competition to hamper performance in CY11.

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 50.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 478

01/26/2011

Company Report

Pages: 2

Consumer business hurts Q4 results

Provider: G.RESEARCH, LLC

Analyst: JONAS J

Price: 10.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 479

01/25/2011

Company Report

Pages: 9

4Q EPS Met Expectations

Provider: J.J.B. Hilliard, W.L. Lyons

Analyst: O'NEIL S

Price: 25.00

Research Provided by a Third Party

Company: Johnson & Johnson

Industry: Large Cap Pharmaceuticals

Record: 480

01/21/2011

Company Report

Pages: 12

Price: 24.95